I recently posted about an organization wanting to recruit patients to do an ethnographic study for a pharmaceutical company of people living with HER2+ MBC.
The company is MacroGenics. They are conducting a Phase III clinical trial of margetumixmab. SOPHIA started in 2015 for MBC HER2+ patients. It compares that drug plus chemotherapy to Herceptin plus chemotherapy in third-line patients.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.